1490 related articles for article (PubMed ID: 27955684)
41. Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial.
Wang Z; Liu J; Ma F; Wang J; Luo Y; Fan Y; Yuan P; Zhang P; Li Q; Li Q; Xu B
Breast Cancer Res Treat; 2021 Jul; 188(2):441-447. PubMed ID: 33895900
[TBL] [Abstract][Full Text] [Related]
42. Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer.
Stefanou D; Kokkali S; Tripodaki ES; Drizou M; Magou E; Zylis D; Prevezanou M; Kapiris M; Nasi D; Ntokou A; Dede M; Ardavanis A
Anticancer Res; 2018 Nov; 38(11):6565-6569. PubMed ID: 30396987
[TBL] [Abstract][Full Text] [Related]
43. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
44. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
[TBL] [Abstract][Full Text] [Related]
45. Chemotherapy de-escalation using an
Pérez-García JM; Gebhart G; Ruiz Borrego M; Stradella A; Bermejo B; Schmid P; Marmé F; Escrivá-de-Romani S; Calvo L; Ribelles N; Martinez N; Albacar C; Prat A; Dalenc F; Kerrou K; Colleoni M; Afonso N; Di Cosimo S; Sampayo-Cordero M; Malfettone A; Cortés J; Llombart-Cussac A;
Lancet Oncol; 2021 Jun; 22(6):858-871. PubMed ID: 34019819
[TBL] [Abstract][Full Text] [Related]
46. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
Burstein HJ; Keshaviah A; Baron AD; Hart RD; Lambert-Falls R; Marcom PK; Gelman R; Winer EP
Cancer; 2007 Sep; 110(5):965-72. PubMed ID: 17614302
[TBL] [Abstract][Full Text] [Related]
47. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
[TBL] [Abstract][Full Text] [Related]
48. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer.
Jahanzeb M; Mortimer JE; Yunus F; Irwin DH; Speyer J; Koletsky AJ; Klein P; Sabir T; Kronish L
Oncologist; 2002; 7(5):410-7. PubMed ID: 12401903
[TBL] [Abstract][Full Text] [Related]
49. First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer.
Araki K; Fukada I; Yanagi H; Kobayashi K; Shibayama T; Horii R; Takahashi S; Akiyama F; Ohno S; Ito Y
Breast; 2017 Oct; 35():78-84. PubMed ID: 28662406
[TBL] [Abstract][Full Text] [Related]
50. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
[TBL] [Abstract][Full Text] [Related]
51. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
Perez EA; Barrios C; Eiermann W; Toi M; Im YH; Conte P; Martin M; Pienkowski T; Pivot XB; Burris HA; Petersen JA; De Haas S; Hoersch S; Patre M; Ellis PA
Cancer; 2019 Nov; 125(22):3974-3984. PubMed ID: 31318460
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.
Toi M; Shao Z; Hurvitz S; Tseng LM; Zhang Q; Shen K; Liu D; Feng J; Xu B; Wang X; Lee KS; Ng TY; Ridolfi A; Noel-Baron F; Ringeisen F; Jiang Z
Breast Cancer Res; 2017 Apr; 19(1):47. PubMed ID: 28399902
[TBL] [Abstract][Full Text] [Related]
53. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.
Andersson M; Lidbrink E; Bjerre K; Wist E; Enevoldsen K; Jensen AB; Karlsson P; Tange UB; Sørensen PG; Møller S; Bergh J; Langkjer ST
J Clin Oncol; 2011 Jan; 29(3):264-71. PubMed ID: 21149659
[TBL] [Abstract][Full Text] [Related]
54. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
Tabernero J; Hoff PM; Shen L; Ohtsu A; Shah MA; Cheng K; Song C; Wu H; Eng-Wong J; Kim K; Kang YK
Lancet Oncol; 2018 Oct; 19(10):1372-1384. PubMed ID: 30217672
[TBL] [Abstract][Full Text] [Related]
55. Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.
Inoue K; Ninomiya J; Saito T; Okubo K; Nakakuma T; Yamada H; Kimizuka K; Higuchi T;
Invest New Drugs; 2019 Jun; 37(3):538-547. PubMed ID: 30848403
[TBL] [Abstract][Full Text] [Related]
56. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D; Ciruelos E; Schneeweiss A; Puglisi F; Peretz-Yablonski T; Campone M; Bondarenko I; Nowecki Z; Errihani H; Paluch-Shimon S; Wardley A; Merot JL; Trask P; du Toit Y; Pena-Murillo C; Revelant V; Klingbiel D; Bachelot T;
Ann Oncol; 2021 Oct; 32(10):1245-1255. PubMed ID: 34224826
[TBL] [Abstract][Full Text] [Related]
57. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.
Shao Z; Pang D; Yang H; Li W; Wang S; Cui S; Liao N; Wang Y; Wang C; Chang YC; Wang H; Kang SY; Seo JH; Shen K; Laohawiriyakamol S; Jiang Z; Li J; Zhou J; Althaus B; Mao Y; Eng-Wong J
JAMA Oncol; 2020 Mar; 6(3):e193692. PubMed ID: 31647503
[TBL] [Abstract][Full Text] [Related]
58. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
[TBL] [Abstract][Full Text] [Related]
59. The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study.
Takahashi M; Ohtani S; Nagai SE; Takashima S; Yamaguchi M; Tsuneizumi M; Komoike Y; Osako T; Ito Y; Ikeda M; Ishida K; Nakayama T; Takashima T; Asakawa T; Matsumoto S; Shimizu D; Masuda N
Breast Cancer Res Treat; 2021 Jan; 185(1):125-134. PubMed ID: 32920732
[TBL] [Abstract][Full Text] [Related]
60. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
